Literature DB >> 14556878

Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.

Donald E Cutlip1, Mark J Ricciardi, Frederick S Ling, Joseph P Carrozza, Vineet Dua, Jason Garringer, Satyendra Giri, Ronald P Caputo.   

Abstract

Sixty-one patients with ST elevation acute myocardial infarction were randomized to receive open-label tirofiban in the emergency room before primary angioplasty versus glycoprotein IIb/IIIa inhibitors administered after initial coronary angiography. Early administration of tirofiban before primary angioplasty resulted in nonsignificant improvement in initial coronary flow (Thrombolysis In Myocardial Infarction trial grade 2 or 3 flow, 39% vs 27%, p >0.20). Patients receiving early tirofiban treatment were more likely to achieve complete (>70%) ST-segment resolution at 90 minutes (69% vs 44%, p = 0.07).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556878     DOI: 10.1016/s0002-9149(03)00983-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Myocardial infarction (ST-elevation).

Authors:  Abel P Wakai
Journal:  BMJ Clin Evid       Date:  2011-01-07

Review 2.  Myocardial infarction (ST-elevation).

Authors:  Abel P Wakai
Journal:  BMJ Clin Evid       Date:  2009-01-09

3.  Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.

Authors:  Henry E Speich; Ronit R Furman; Lindsey T Lands; Geoffrey D Moodie; Lisa K Jennings
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

4.  Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation.

Authors:  Giuseppe De Luca; C Michael Gibson; Francesco Bellandi; Sabina Murphy; Mauro Maioli; Marko Noc; Uwe Zeymer; Dariusz Dudek; Hans-Richard Arntz; Simona Zorman; H Mesquita Gabriel; Ayse Emre; Donald Cutlip; Tomasz Rakowski; Mariann Gyongyosi; Kurt Huber; Arnoud W J Van't Hof
Journal:  J Thromb Thrombolysis       Date:  2008-11-22       Impact factor: 2.300

Review 5.  Antithrombotic therapies in primary angioplasty: rationale, results and future directions.

Authors:  Giuseppe De Luca; Paolo Marino
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  ST-segment resolution and prognosis after facilitated versus primary percutaneous coronary intervention in acute myocardial infarction: a meta-analysis.

Authors:  Ingo Eitel; Annegret Franke; Gerhard Schuler; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2009-08-29       Impact factor: 5.460

Review 7.  Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

Authors:  Arnoud W J van 't Hof; Marco Valgimigli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Effect of Early Treatment With Tirofiban on Initial TIMI Grade 3 Flow of Patients With ST Elevation Myocardial Infarction.

Authors:  Mojtaba Salarifar; Mehdi Mousavi; Narges Yousefpour; Ebrahim Nematipour; Seyed Ebrahim Kassaian; Hamidreza Poorhosseini; Alimohammad Hajizeinali; Mohammad Alidoosti; Hassan Aghajani; Younes Nozari; Alireza Amirzadegan; Ali Bozorgi; Yaser Genab
Journal:  Iran Red Crescent Med J       Date:  2014-01-05       Impact factor: 0.611

Review 9.  Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead.

Authors:  Enrico Fabris; Serge Korjian; Barry S Coller; Jurrien M Ten Berg; Christopher B Granger; C Michael Gibson; Arnoud W J van 't Hof
Journal:  Thromb Haemost       Date:  2021-04-30       Impact factor: 6.681

Review 10.  Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.

Authors:  G De Luca; C M Gibson; F Bellandi; S Murphy; M Maioli; M Noc; U Zeymer; D Dudek; H-R Arntz; S Zorman; H M Gabriel; A Emre; D Cutlip; G Biondi-Zoccai; T Rakowski; M Gyongyosi; P Marino; K Huber; A W J van't Hof
Journal:  Heart       Date:  2008-05-12       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.